Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Nerinetide (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms FRONTIER
- Sponsors NoNO
- 11 May 2023 Status changed from active, no longer recruiting to completed.
- 06 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2022 Planned number of patients changed from 558 to 586.